Investor Presentaiton

SAR-bisPSMA therapy in prostate cancer SECURE PET scans in a patient with metastatic castrate-resistant prostate cancer imaged over multiple timepoints between 1 and 72 hours post administration of 64CU SAR-bisPSMA (Normalised Voxel Intensity) CLARITY 2014 MEIE Y Y Y Y Y 1h post injection 12h post injection 24h post injection 48h post injection 72h post injection 14

View entire presentation